IN THE NEWS
-
COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY
Dear IntegraGen customers and partners, We care about your satisfaction and understand that the entire community is impacted by COVID-19. That's why we're working hard to maintain... Read More
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur relating to high throughput sequencing operations for microbiology activities carried out... Read More
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that miR-31 expression levels identify sub-populations of cancer patients... Read More
LATEST NEWS
-
PUBLICATION IN BIOMARKER INSIGHTS OF TECHNICAL VALIDATION DATA FOR THE MIR-31-3P TEST
IntegraGen is pleased to announce that a full summary of the results of the validation studies for... Read More
-
INTEGRAGEN: A STRUCTURING DOUBLE AGREEMENT WITH TWIST BIOSCIENCE - INTERVIEW WITH BERNARD COURTIEU IN BIOTECH FINANCE
Bernard Courtieu answers questions from Pierre-Louis Germain, "Biotech Finance" specialist journalist, about the... Read More
-
PRESENTATION OF NEW RESULTS ON THE MIR-31-3P BIOMARKER IN AN ORAL PRESENTATION AT THE ESMO 2016 CONGRESS IN COPENHAGEN
The results of new analyses carried out on the FIRE-3 trial on the predictive role of the marker... Read More
-
RESULTS OF MIR-31-3P EXPRESSION ANALYSIS IN THE FIRE-3 STUDY TO BE PRESENTED AT THE ASCO 2016 CONGRESS
he results of mir31-3p expression analysis in the FIRE-3 colon cancer study... Read More
